Cargando…

Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice

BACKGROUND: The capacity of the recombinant Vaccinia virus GLV-1h68 as a single agent to efficiently treat different human or canine cancers has been shown in several preclinical studies. Currently, its human safety and efficacy are investigated in phase I/II clinical trials. In this study we set ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofmann, Elisabeth, Weibel, Stephanie, Szalay, Aladar A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105246/ https://www.ncbi.nlm.nih.gov/pubmed/25030093 http://dx.doi.org/10.1186/1479-5876-12-197

Ejemplares similares

Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice
por: Chen, Nanhai G, et al.
Publicado: (2011)

Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps
por: Kober, Christina, et al.
Publicado: (2015)

Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer
por: Kober, Christina, et al.
Publicado: (2015)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody
por: Patil, Sandeep S., et al.
Publicado: (2012)

Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice
por: Donat, Ulrike, et al.
Publicado: (2012)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
por: Gentschev, Ivaylo, et al.
Publicado: (2012)

Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells
por: Kilinc, Mehmet Okyay, et al.
Publicado: (2016)

Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models
por: Cecil, Alexander, et al.
Publicado: (2019)

Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2011)

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
por: Worschech, Andrea, et al.
Publicado: (2009)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
por: Adelfinger, Marion, et al.
Publicado: (2014)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Synergistic Antitumor Effect of Grifola frondose Polysaccharide—Protein Complex in Combination with Cyclophosphamide in H22 Tumor-Bearing Mice
por: Zhao, Jiahui, et al.
Publicado: (2023)

Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer
por: Weibel, Stephanie, et al.
Publicado: (2013)

Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection
por: Weibel, Stephanie, et al.
Publicado: (2011)

Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors
por: Schäfer, Simon, et al.
Publicado: (2012)

Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells
por: Wang, Huiqiang, et al.
Publicado: (2012)

The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation
por: Zhang, Qian, et al.
Publicado: (2009)

Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
por: Liu, Liqiong, et al.
Publicado: (2022)

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
por: Adelfinger, Marion, et al.
Publicado: (2015)

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
por: Draganov, Dobrin D., et al.
Publicado: (2019)

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy
por: Haddad, Dana, et al.
Publicado: (2016)

Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68
por: Ehrig, Klaas, et al.
Publicado: (2013)

Oncolytic Viruses
por: Chen, Nanhai G., et al.
Publicado: (2012)

Imaging of Intratumoral Inflammation during Oncolytic Virotherapy of Tumors by (19)F-Magnetic Resonance Imaging (MRI)
por: Weibel, Stephanie, et al.
Publicado: (2013)

Correction to: Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
por: Draganov, Dobrin D., et al.
Publicado: (2021)

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a “Trojan Horse” in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas
por: Petrov, Ivan, et al.
Publicado: (2020)

Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis
por: Tsoneva, Desislava, et al.
Publicado: (2017)

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity
por: Hirvinen, Mari, et al.
Publicado: (2016)

Beneficial effects of 20(S)-protopanaxadiol on antitumor activity and toxicity of cyclophosphamide in tumor-bearing mice
por: LIN, GUANGZHU, et al.
Publicado: (2013)

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
por: Ascierto, Maria Libera, et al.
Publicado: (2011)

Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter
por: Haddad, Dana, et al.
Publicado: (2012)

Oncolytic Virotherapy of Canine and Feline Cancer
por: Gentschev, Ivaylo, et al.
Publicado: (2014)

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
por: Minev, Boris R., et al.
Publicado: (2019)

Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
por: Ge, Yan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6svi73p472rqddh55rn02cjjrp